Sanofi and Alnylam Exercise Research and Option Phase Collaboration for its 2014 Deal

 Sanofi and Alnylam Exercise Research and Option Phase Collaboration for its 2014 Deal

Sanofi and Alnylam Exercise Research and Option Phase Collaboration for its 2014 Deal

Shots:

  • Alnylam to add an additional investigational product through the end of IND-enabling studies in Sanofi’s subsidiary Genzyme and Alnylam in 2014 deal, where companies collaborated to develop and commercialize RNAi therapeutics for undisclosed rare disease
  • Sanofi to take care of clinical development and commercialization of a product. Post-approval Alnylam to receive royalties on WW sales from Sanofi. Additionally, Sanofi agreed to release the shares of Alnylam (12% acquired at $80/share, in 2014)
  • In 2012, the companies initially collaborated to develop RNAi therapies including ALN-TTR02 (Patisiran) & ALN-TTRsc02 (Vutrisiran) for ATTR in Japan & Asia. In 2018, the companies further restructured the 2014 alliance with the addition of Fitusiran

Click here to read full press release/ article | Ref: Sanofi | Image: Behance

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post